FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileZymeworks Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZYME
Zymeworks Inc. Stock AnalysisComprehensive stock analysis for Zymeworks Inc. (ZYME) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisZYME
ZYME
Zymeworks Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZYME
  1. Home
  2. Stocks
  3. Zymeworks Inc.

Zymeworks Inc.

🇺🇸ZYME•NASDAQ

Zymeworks Inc.

🇺🇸ZYME•NASDAQ
Market cap
$1.81B
P/E ratio
38.89

Your view on ZYME

Mkt Cap
$1.81B
P/E
38.89
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Zymeworks Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Kenneth H. Galbraith
Headquarters
114 East 4th Avenue, Middletown, BC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Kenneth H. Galbraith
Headquarters
114 East 4th Avenue, Middletown, BC, CA
Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.

The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Zymeworks Inc.. Starting points for Zymeworks Inc.: P/E 38.9, EPS $0.60, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Zymeworks Inc.. Trailing twelve-month EPS for Zymeworks Inc. stands at $0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$42.11

average of 9 firms, last 12 months

 

$42.11

Low $32.00

Median $40.00

High $55.00

 

Analyst Ratings

Buy11 firms, last 12 months
  • Strong Buy0
  • Buy11
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.13−$0.14$1.27$0.69
Low estimate$0.06−$0.36$1.06−$2.08
High estimate$0.33$0.08$1.82$4.11
No. of analysts6278
Year-ago EPS−$0.55−$0.591−$1.081—
Growth+122.9%———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$72.52M$73.20M$334.28M$342.62M
Low estimate$44.19M$31.42M$330.55M$184.92M
High estimate$86.40M$114.97M$338.71M$528.90M
No. of analysts2188
Year-ago revenue$2.52M$2.41M$105.97M—
Growth+2783.3%+2939.8%+215.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 13, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Zymeworks Inc.. Zymeworks Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ZYME20 companies · 8 funds
Compare ZYME with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ADCTADC Therapeutics S.A.HealthcareBiotechnology$192.7M
ALXOALX Oncology Holdings Inc.HealthcareBiotechnology$134.1M
CBIOCrescent Biopharma, Inc.HealthcareBiotechnology$482.3M
CGENCompugen Ltd.HealthcareBiotechnology$185.7M
CLDXCelldex Therapeutics, Inc.HealthcareBiotechnology$2.2B
CTMXCytomX Therapeutics, Inc.HealthcareBiotechnology$409.8M
IMNMImmunome, Inc.HealthcareBiotechnology$2.0B
MGNXMacroGenics, Inc.HealthcareBiotechnology$125.9M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
XRTX.VXORTX Therapeutics Inc.HealthcareTSXV—
XSNXNovAccess Global Inc.HealthcareOTC$6,165
XTLBXTL Biopharmaceuticals Ltd.HealthcareNASDAQ$1.5M
YARWYarrow Bioscience IncHealthcareNASDAQ$135.4M
YDESYD Bio Limited Ordinary SharesHealthcareNASDAQ$343.5M
YDESWYD Bio Limited WarrantsHealthcareNASDAQ$1.4M
YECOYulong Eco-Materials LimitedHealthcareOTC$592,481
ZBIOZenas BioPharma, Inc.HealthcareNASDAQ$1.8B
ZEOXZeo ScientifiX, Inc.HealthcareOTC$15.4M
ZHCLFZenith Capital Corp.HealthcareOTC$15.9M
ZIVOZIVO Bioscience, Inc.HealthcareOTC$36.4M
ZLABZai Lab LimitedHealthcareNASDAQ$2.5B
ETFs holding Zymeworks Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.04%
IWMiShares Russell 2000 ETF$76.6B in assets0.04%
IBBiShares Biotechnology ETF$11.1B in assets0.13%
BBPVirtus LifeSci Biotech Products ETF$133M in assets1.57%
CANCTema Oncology ETF$215M in assets1.21%
DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets0.41%
FSMLFranklin Small Cap Enhanced ETF$146M in assets0.36%

Largest holders first, then the funds most concentrated in ZYME.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Zymeworks Inc., and how their positions are changing. At a $1.81B market value, institutional positions materially move Zymeworks Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Zymeworks Inc. executives and directors. Shares of Zymeworks Inc. have traded between $9.03 and $26.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Zymeworks Inc.. Coverage tracks Zymeworks Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Zymeworks Inc.

ZYME AnalysisFair
Past
3
Growth
1
Health
2
Profit
3
Value
1

News

Latest Market News